Donald McCaffrey
Chief Executive Officer at RESVERLOGIX CORP.
Net worth: 513 843 $ as of 2024-06-29
Donald McCaffrey active positions
| Companies | Position | Start | End |
|---|---|---|---|
| RESVERLOGIX CORP. | Chief Executive Officer | 2003-04-24 | - |
| Chairman | 2016-04-03 | - | |
| Founder | 2000-08-16 | - | |
| President | 2003-04-24 | - | |
| Corporate Secretary | 2003-04-24 | - | |
| Director/Board Member | 2003-04-24 | 2016-04-03 | |
| Public Communications Contact | 2011-02-16 | 2012-09-24 | |
| ZENITH CAPITAL CORP. | Chief Executive Officer | 2013-04-09 | - |
| Chairman | 2013-04-09 | - | |
| Founder | 2013-04-09 | - | |
| President | 2013-04-09 | - | |
| Corporate Secretary | 2013-04-09 | - |
Career history of Donald McCaffrey
Former positions of Donald McCaffrey
| Companies | Position | Start | End |
|---|---|---|---|
| TRILLIUM THERAPEUTICS | Director/Board Member | 2004-10-31 | 2006-03-26 |
| PROMIS NEUROSCIENCES, INC. | Director/Board Member | - | - |
Statistics
International
| Canada | 5 |
Operational
| Director/Board Member | 3 |
| Chief Executive Officer | 2 |
| Chairman | 2 |
Sectoral
| Health Technology | 5 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| RESVERLOGIX CORP. | Health Technology |
| ZENITH CAPITAL CORP. | Health Technology |
| Private companies | 1 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Donald McCaffrey
- Experience
